COSCIENS Biopharma Inc T.CSCI

RE:Jolyon Burton

[prophetoffactz]

"Regardless of the above, I guess that must mean that that $2 million spent on legal fees prior to announcing the deal was a significant or "Material" amount.  This is where "disclosure" comes into play because it would have been prudent for Gilles Gagon to provide a news release stating an intention to merge prior to embarking on the big legal fee spending spree.  He could have done this but chose not to."

It was publically known that CZO was actively planning to uplist to NASDAQ. 
 

1. In August 2023, Ceapro mentioned "continued planning for uplisting to Nasdaq" as part of their corporate update in their Q2 2023 financial results announcement.
2. This interest was reiterated in their Q3 2023 financial results, where they again mentioned "ongoing strategic corporate discussions progressing and continued planning for uplisting to Nasdaq"

This is my post based on the 2023 AGM:

 

TSXV:CZO Forum Post | prophetoffactz-35487688 | NASDAQ Uplisting: | Ceapro Inc (stockhouse.com)

(106)
•••

Post by prophetoffactzon Jun 08, 2023 9:22pm

186 Views 

Post# 35487688

NASDAQ Uplisting:

Uplisting to an international exchange such as NASDAQ is not only a goal for 2023, with only about six months left in the year, it was regarded as very important by Gilles at the AGM if the company is going to unlock value and advance as a biopharma. The company needs greater exposure. Acquiring other products on the market is also being looked at. The company has already actively investigated listed companies for a potential reverse-takeover in the US. 

...

An uplisting to an international exchange is back in CZO's priorities. Reverse mergers have been investigated as one option. Given the historic bear market in biotech there may be an opportunity to reverse merge with another company as they struggle.